Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2026 ,inter alia, to consider and approve 1. The Unaudited Standalone ....
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bliss GVS Pharma has informed the stock exchanges that its Board of Directors will meet on Tuesday, February 10, 2026, at the registered office. The agenda includes considering and approving the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025 (Q3 FY26 results). The Board will also consider declaring an Interim Dividend, if any, for the financial year 2025-2026. The trading window for designated persons has been closed since January 1, 2026, and will remain closed until 48 hours after the results are announced.
This is a routine regulatory intimation ahead of the Q3 FY26 earnings announcement. Investors should watch for the actual results on February 10, 2026, particularly any declaration of an interim dividend, which would be a positive signal for shareholders.